News & Insights The Latest in Medtech Innovation

The LaunchPort virtual resident Brevitest moves closer to launch of COVID-19 Antibody test

BreviTest Technologies announced that the FDA has officially accepted BreviTest’s notification of its intent to commercially distribute its IgG antibody test.  The BreviTest SARS-CoV-2 IgG Test detects the presence of SARS-CoV-2 specific IgG antibodies in plasma or serum using only 3μl of sample. Reliable results are available in 10 minutes. A positive test result indicates prior exposure to the virus and potential immunity.

News Article
Get Started

Let’s build something together.

The LaunchPort | Copyright 2020 | All rights reserved